Rays of Belief IPO: GMP, Day 1 demand, risks

Rays of Belief IPO snapshot investors are sharing

Rays of Belief has opened its IPO for subscription on September 1, 2026, and it closes on September 3, 2026. The issue size is Rs 125 crore. Social media posts repeatedly highlight that the IPO is entirely a fresh issue of 52.30 lakh shares. The price band is set at Rs 227 to Rs 239 per share. The lot size is 62 shares, and several trackers show the minimum retail investment around Rs 14,074 to Rs 14,818 depending on the price used. The basis of allotment is expected to be finalised on September 4, 2026. Listing is tentatively scheduled for September 8, 2026. The shares are slated to list on both NSE and BSE.

Grey market premium is upbeat, but not a guarantee

Discussion is dominated by the grey market premium (GMP), which is being treated as a sentiment gauge ahead of listing. Multiple posts put GMP at Rs 48, described as roughly a 20% premium over the upper price band of Rs 239. Based on that Rs 48 GMP, some estimates place the indicative listing price near Rs 287 per share. Another update in the same stream places GMP at Rs 38 on September 1, implying an estimated listing price around Rs 277 and a potential gain near 15.90% over the cap price. Commentators also stress that GMP is unofficial and can fluctuate sharply before listing. Several notes explicitly warn that GMP does not guarantee the actual listing price. This matters because the online narrative is currently anchored to GMP-based listing estimates. Investors tracking listing gains are therefore watching whether the premium holds into the close and allotment.

Subscription on Day 1: retail leads the demand

Day 1 subscription data shared widely shows the issue crossing around 1.13x to 1.18x overall by market close on September 1, as per NSE data references in posts. The key highlight is retail participation. Retail Individual Investors (RIIs) subscribed their portion about 6.25x to 6.51x in the data points circulating. That retail oversubscription is being interpreted as a sign of strong early interest, even while overall subscription is modest on Day 1. Another set of posts notes NII (bHNI) movement during the day, rising from 0.19x to 0.83x, described as a sharp pick-up. Social threads also mention the overall subscription reading around 1.05x to 1.18x at different timestamps, indicating updates throughout the day. The takeaway from the chatter is clear: the early book is being carried by retail demand.

Key IPO details in one place

The following details are repeatedly cited across trackers and discussions. The numbers below reflect what is being shared, including slight variations in live GMP snapshots.

What the company profile posts focus on

Rays of Belief is being described as the parent company of Mom's Belief in the posts. Several summaries cite its positioning in the behavioral health domain, stating it ranks first in India and seventh globally among listed players in that domain. One widely shared fact-set says it operated 136 centres across 57 cities and 20 states and union territories in India as of March 31, 2026. The same set breaks the footprint into 42 centres in Tier 1, 77 centres in Tier 2, and 17 centres in Tier 3 cities. Commentators present this as a deliberate push beyond major urban hubs and into underrepresented geographies. The expansion narrative is often paired with the subscription and GMP discussion to support the idea of strong demand. At the same time, some posts caution that scale and footprint do not remove execution and concentration risks. The market tone is therefore a mix of growth visibility and risk reminders.

Financial trend points being circulated

Social posts share a sharp rise in revenue from operations from Rs 306.08 million in Fiscal 2024 to Rs 816.62 million in Fiscal 2026, with a stated CAGR of 63.34%. EBITDA is also cited as improving from Rs 14.91 million in Fiscal 2024 to Rs 119.11 million in Fiscal 2026. Another shared datapoint says revenue increased by 125% and PAT dropped by 16% between the year ending March 31, 2026 and March 31, 2025. Margin metrics are also being quoted: PAT margin at 6.07% for March 31, 2026 versus 16.15% for March 31, 2025, and EBITDA margin at 14.59% versus 8.28%. Return ratios are being discussed too, with ROE at 21.64% versus 56.56%, and ROCE at 29.74% versus 7.49%. These mixed signals are driving the split opinions seen online, especially between listing-focused applicants and longer-term investors.

Risks flagged: cash flows, leases, and concentration

The risk list circulating in posts includes negative operating cash flows. Another repeated risk is dependency on short-term leases, which can create operational uncertainty if renewals or locations become an issue. Concentration risk is being discussed at multiple levels. One note says that during Fiscal 2026, 15.36% of revenue from operations came from centres in Uttar Pradesh, Karnataka and Delhi, and 17.58% from Tier 2 cities, implying regional exposure that could impact performance if conditions change. Related-party exposure also features prominently: one post states 25.56% of revenue from operations in Fiscal 2026 was derived from export services to related parties (Carving Futures Pte. Ltd. and Carving Futures Inc.). Another flags that 50.21% of pro forma revenue for Fiscal 2025 came from three newly acquired US centres, calling it a significant concentration risk. These points are why some social commentators label the IPO as higher risk despite strong retail bidding.

Valuation and expert views: mixed, not one-way bullish

A widely shared summary card lists “Chanakya View” as “Avoid at Present” with an overall rating shown as 2.5/5. The same view says it may be suitable for listing gains only if GMP remains strong, while long-term suitability is marked negative due to “valuation is expensive.” Risk level is labelled “High” in that card. Valuation metrics shared in posts include EPS (pre IPO) at Rs 3.16 and (post IPO) at Rs 2.37. The P/E ratios cited are 75.63x pre-IPO and 100.84x post-IPO. These are the exact datapoints being debated across forums, especially by investors comparing GMP-led listing expectations to valuation comfort for holding beyond listing. The overall tone is that the listing thesis is being driven more by sentiment indicators than by consensus on fundamentals. That is why many posts keep returning to GMP durability as the key short-term variable.

What to watch into allotment and listing day

Between now and September 4 allotment, the social focus is likely to stay on two live indicators: subscription trend by category and GMP movement. Several posts already point out that GMP has fluctuated over recent sessions, with a range cited from Rs 0 to Rs 48 across 13 sessions. If GMP holds near the higher end, listing-gain expectations remain elevated in online chatter, but commenters also repeat that it is not a reliable predictor. On the demand side, investors are watching whether non-retail categories catch up after retail-led Day 1 bidding. Another practical watchpoint is whether discussion shifts from “listing pop” to the business risks being highlighted, including related-party revenue concentration and reliance on specific geographies. For listing-day expectations, the only concrete numbers being used in discussions are the cap price of Rs 239 and GMP-based indicative prices around Rs 277 to Rs 287. Any plan built around those levels should account for how quickly these indicators can change.